Mobia Medical closed at $11.24 on Nov 4, up 12.74%, 4.7% below its highest close since Sep 28. Volume of 380.3K shares was 2.48× its 20-day average (well above normal).
Split-adjusted performance: +27.7% over one month.
In the quarter ended Jun 30, 2026, revenue was $13.51M, with a net margin of -155.8%.
Short interest was 850.2K shares at the Oct 15 settlement, down 21.6% from the prior report (7.4% of float, 6.5 days to cover).
No reported quarters with price history yet.
Percentile among 110 companies (100 = best)
Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| MOBIMobia Medical | $11.24 | +12.74% | — | — | −155.8% | — | $374.2M | |
| EMBCEmbecta | $6.52 | +7.24% | +83.1% | −8.1% | 7.8% | 4.2 | $369.4M | Compare |
| OBIOOrchestra BioMed Holdings | $6.00 | +7.91% | +46.0% | −89.5% | −27362.5% | — | $360.6M | Compare |
| OFIXOrthofix Medical Inc. Common Stock (DE) | $9.72 | +10.96% | −20.3% | +3.8% | −7.5% | — | $395.9M | Compare |
| CLPTClearPoint Neuro | $10.16 | +4.63% | −11.4% | +36.3% | −61.8% | — | $325.7M | Compare |
| SIShoulder Innovations | $21.01 | +6.00% | +63.0% | — | −59.1% | — | $437.4M | Compare |
| CARLCarlsmed | $16.09 | +11.74% | +63.5% | — | −55.5% | — | $439.3M | Compare |
| SSIISS Innovations International | $2.27 | −2.58% | −44.2% | +39.4% | −19.1% | — | $455.1M | Compare |
| NPCENeuropace | $13.34 | +8.37% | −26.4% | +17.1% | −27.2% | — | $457.9M | Compare |
No recent articles focused on Mobia Medical.
Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. The company develops, markets and sells devices for the treatment of medical conditions. Its flagship device is the Vivistim Paired Vagus Nerve Stimulation system, which is used to support motor function rehabilitation in patients with chronic ischemic stroke. The company generates all of its revenue from the sale of the Vivistim System to customers, mainly primary and comprehensive stroke centers, in the United States.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
